X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1290) 1290
Publication (108) 108
Book Review (17) 17
Magazine Article (4) 4
Newsletter (3) 3
Book Chapter (1) 1
Conference Proceeding (1) 1
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1086) 1086
index medicus (831) 831
male (809) 809
rosuvastatin (793) 793
rosuvastatin calcium (780) 780
female (710) 710
middle aged (617) 617
statins (540) 540
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (519) 519
aged (479) 479
fluorobenzenes - therapeutic use (441) 441
pyrimidines - therapeutic use (426) 426
sulfonamides - therapeutic use (424) 424
atorvastatin (410) 410
pharmacology & pharmacy (367) 367
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (366) 366
cholesterol (353) 353
treatment outcome (322) 322
cardiac & cardiovascular systems (311) 311
adult (305) 305
fluorobenzenes - adverse effects (289) 289
pyrimidines - adverse effects (280) 280
sulfonamides - adverse effects (278) 278
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (275) 275
simvastatin (253) 253
cholesterol, ldl - blood (241) 241
fluorobenzenes - administration & dosage (226) 226
pyrimidines - administration & dosage (213) 213
sulfonamides - administration & dosage (211) 211
risk factors (205) 205
risk (202) 202
pravastatin (199) 199
atorvastatin calcium (196) 196
antilipemic agents (190) 190
hypercholesterolemia - drug therapy (178) 178
cardiovascular (175) 175
drug therapy (167) 167
cardiovascular disease (163) 163
lipids (163) 163
medicine, general & internal (162) 162
prevention (158) 158
dose-response relationship, drug (154) 154
hypercholesterolemia (154) 154
atherosclerosis (153) 153
c-reactive protein (152) 152
animals (150) 150
analysis (146) 146
abridged index medicus (145) 145
double-blind method (145) 145
safety (145) 145
therapy (145) 145
coronary-heart-disease (138) 138
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (137) 137
efficacy (136) 136
statin therapy (136) 136
fluorobenzenes - pharmacology (134) 134
drug therapy, combination (133) 133
care and treatment (132) 132
dosage and administration (132) 132
heptanoic acids - therapeutic use (130) 130
pyrroles - therapeutic use (129) 129
sulfonamides - pharmacology (126) 126
pyrimidines - pharmacology (125) 125
research (125) 125
statin (125) 125
pharmacokinetics (120) 120
drug interactions (119) 119
cardiovascular diseases - prevention & control (116) 116
cardiovascular-disease (116) 116
low density lipoproteins (116) 116
prospective studies (116) 116
aged, 80 and over (115) 115
disease (112) 112
mortality (110) 110
density-lipoprotein cholesterol (109) 109
rosuvastatin calcium - therapeutic use (108) 108
anticholesteremic agents - therapeutic use (106) 106
time factors (106) 106
internal medicine (103) 103
metaanalysis (103) 103
dyslipidemias - drug therapy (101) 101
cardiovascular diseases (97) 97
clinical trials (97) 97
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (95) 95
cardiovascular agents (93) 93
health aspects (93) 93
diabetes (92) 92
hyperlipidemias - drug therapy (92) 92
rosuvastatin calcium - administration & dosage (92) 92
biomarkers - blood (91) 91
cardiology (91) 91
follow-up studies (90) 90
myocardial-infarction (90) 90
rosuvastatin calcium - adverse effects (89) 89
ezetimibe (88) 88
inflammation (88) 88
primary prevention (88) 88
randomized controlled trials as topic (88) 88
cholesterol - blood (86) 86
dyslipidemia (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1271) 1271
German (4) 4
Russian (4) 4
Spanish (4) 4
Chinese (3) 3
Italian (3) 3
Dutch (2) 2
French (2) 2
Czech (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2021 - 2031
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
In a 2-by-2 factorial trial, 12,705 persons at intermediate risk were assigned to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin or... 
STROKE | MORTALITY | TRIALS | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | COUNTRIES | THERAPY | MYOCARDIAL-INFARCTION | STRATEGY | PREVENTION | INTERHEART | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 18, pp. 1744 - 1753
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2015, Volume 71, Issue 3, pp. 341 - 355
Systemic exposure to rosuvastatin is approximately double that of Caucasians in Asian subjects. We investigated whether this pattern of increased exposure... 
SLCO1B1 | Pharmacogenetics | Biomedicine | Caucasian | Pharmacology/Toxicology | Pharmacokinetics | Asian | ABCG2 | WHITE | ADULT MALE-VOLUNTEERS | RISK | OATP1B1 | DISPOSITION | MARKEDLY AFFECTS | TRANSPORT | SYSTEMIC EXPOSURE | DISEASE | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Simvastatin - adverse effects | Atorvastatin Calcium - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Simvastatin - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | ATP-Binding Cassette Transporters - genetics | Adult | Female | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Atorvastatin Calcium - pharmacokinetics | European Continental Ancestry Group - genetics | Rosuvastatin Calcium - pharmacokinetics | Genotype | Simvastatin - pharmacokinetics | Simvastatin - analogs & derivatives | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adolescent | Polymorphism, Single Nucleotide - genetics | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Genetic aspects | Rosuvastatin | Simvastatin | Antilipemic agents | Genotype & phenotype | Whites | Pharmacology | Statins | Asians | Polymorphism
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2017, Volume 57, Issue 10, pp. 1305 - 1314
Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease. It inhibits multiple cytochrome P‐450 enzymes and multiple membrane... 
faldaprevir | atorvastatin | rosuvastatin | drug–drug Interaction | COA REDUCTASE INHIBITOR | CHRONIC HEPATITIS-C | LIVER FIBROSIS | TRANSPLANT RECIPIENTS | INTERFERON-FREE | DRUG TRANSPORTERS | THERAPY | drug-drug Interaction | BI 201335 | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITOR FALDAPREVIR | Atorvastatin Calcium - analogs & derivatives | Atorvastatin Calcium - blood | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Healthy Volunteers | Oligopeptides - adverse effects | Thiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Drug Interactions | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Serine Proteinase Inhibitors - pharmacology | Atorvastatin Calcium - pharmacokinetics | Antiviral Agents - pharmacology | Rosuvastatin Calcium - pharmacokinetics | Cross-Over Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Thiazoles - pharmacology | Oligopeptides - pharmacology | Rosuvastatin | Dosage and administration | Hepatitis C | Drug therapy | Pharmacokinetics | Analysis | Metabolites | Viruses | Cytochromes | Pharmacology | Hepatitis C virus | Drug dosages | Steady state
Journal Article
Journal Article
Epilepsy Research, ISSN 0920-1211, 2017, Volume 135, pp. 64 - 70
Journal Article
International Journal of Clinical Pharmacology and Therapeutics, ISSN 0946-1965, 2017, Volume 55, Issue 3, pp. 286 - 294
Context: A fixed-dose combination (FDC) of candesartan and rosuvastatin was recently developed for the treatment of cardiovascular disease and expected to... 
Rosuvastatin calcium | Candesartan cilexetil | Bioequivalence study | Angiotensin receptor blocker | Fixed-dose combination | HMG-CoA reductase | EFFICACY | rosuvastatin calcium | VOLUNTEERS | angiotensin receptor blocker | OPEN-LABEL | fixed-dose combination | STATINS | candesartan cilexetil | bioequivalence study | 2-PERIOD | PHARMACOLOGY & PHARMACY | CROSSOVER | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tablets | Area Under Curve | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Half-Life | Male | Metabolic Clearance Rate | Healthy Volunteers | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Rosuvastatin Calcium - administration & dosage | Tetrazoles - blood | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Adult | Biphenyl Compounds - blood | Benzimidazoles - adverse effects | Rosuvastatin Calcium - blood | Benzimidazoles - blood | Republic of Korea | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Biphenyl Compounds - pharmacokinetics | Administration, Oral | Rosuvastatin Calcium - pharmacokinetics | Benzimidazoles - pharmacokinetics | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - adverse effects | Antihypertensive Agents - blood | Cross-Over Studies | Asian Continental Ancestry Group | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Biphenyl Compounds - administration & dosage | Angiotensin II Type 1 Receptor Blockers - blood | Tetrazoles - adverse effects | Drug Combinations | Tetrazoles - pharmacokinetics | Therapeutic Equivalency | Pharmaceutical industry
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 09/2018, Volume 104, Issue 3, pp. 525 - 533
Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and hepatic transporter‐mediated accumulation in the liver enhances its efficacy.... 
VARIABILITY | DRUG | ACID | PHARMACOKINETICS | TRANSPORTERS | HMG-COA REDUCTASE | PHARMACOLOGY & PHARMACY | PHARMACOGENETICS | PHARMACODYNAMICS | POLYMORPHISM | ATORVASTATIN | Dyslipidemias - genetics | Prospective Studies | Rosuvastatin Calcium - therapeutic use | ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism | Dyslipidemias - ethnology | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Asian Continental Ancestry Group - genetics | Male | Neoplasm Proteins - metabolism | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Dyslipidemias - blood | Canada - epidemiology | Fasting - blood | Postprandial Period | Pharmacogenomic Variants | Adult | Cholesterol, LDL - blood | Female | Muscular Diseases - chemically induced | Neoplasm Proteins - genetics | Rosuvastatin Calcium - blood | Dyslipidemias - drug therapy | European Continental Ancestry Group - genetics | Risk Assessment | Rosuvastatin Calcium - pharmacokinetics | Down-Regulation | Food-Drug Interactions | Mice, Inbred C57BL | ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics | Treatment Outcome | Biomarkers - blood | Cross-Over Studies | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Mice | Muscular Diseases - genetics
Journal Article
Pharmacological Research, ISSN 1043-6618, 05/2016, Volume 107, pp. 1 - 18
Journal Article